PF-Atlas › Clinical Trials › TETON-2

Inhaled Treprostinil for IPF — TETON-2 Phase III

Inhaled Treprostinil · Prostacyclin Analog · Phase 3

Registry ID
TETON-2
Phase
Phase 3
Status
Completed
Drug / intervention
Inhaled Treprostinil
Mechanism
Prostacyclin Analog
Sponsor
United Therapeutics
Start
2021-09

About this trial

Inhaled Treprostinil is evaluated in TETON-2, a Phase 3 idiopathic pulmonary fibrosis study sponsored by United Therapeutics, targeting prostacyclin analog. Current status: Completed.

View TETON-2 on ClinicalTrials.gov →

Explore related

Inhaled Treprostinil / Tyvaso — Treatment profileAll Inhaled Treprostinil trialsProstacyclin Analog mechanismAll IPF trials

Related trials

Inhaled Treprostinil — TETON-1Inhaled Treprostinil — NCT04905693
Medical disclaimer. This page summarizes public trial data for TETON-2 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.